PMID- 34265292
OWN - NLM
STAT- MEDLINE
DCOM- 20220106
LR  - 20220106
IS  - 1879-0712 (Electronic)
IS  - 0014-2999 (Linking)
VI  - 908
DP  - 2021 Oct 5
TI  - Luteolin mitigates tamoxifen-associated fatty liver and cognitive impairment in 
      rats by modulating beta-catenin.
PG  - 174337
LID - S0014-2999(21)00490-8 [pii]
LID - 10.1016/j.ejphar.2021.174337 [doi]
AB  - BACKGROUND AND AIM: Tamoxifen (TAM) therapy has been associated with fatty liver 
      diseases. Recently, multiple reports have also shown that TAM is related to 
      cognitive impairment in patients with breast cancer. Luteolin, a natural 
      flavonoid, has been traditionally used to treat various inflammatory disorders, 
      such as chronic liver diseases, cognitive impairments, and cancers. This study 
      aimed to evaluate the potential protective effects of luteolin against the 
      cognitive defects and liver steatosis induced by TAM in rats. EXPERIMENTAL 
      APPROACH: The diseased group was subcutaneously (s.c) injected with TAM at a dose 
      of 1 mg/kg daily for 7 days. The cotreated groups were given luteolin via oral 
      gavage at a dose of 20 or 40 mg/kg concomitantly with s.c injection of TAM at a 
      dose of 1 mg/kg for 7 days. All the groups were subjected to behavioral tests 
      24 h after the last TAM injection. Then, the rats were sacrificed 3 days after 
      the last TAM injection. RESULTS: Luteolin cotreatment significantly alleviated 
      the behavioral defects in rats with TAM-induced cognitive impairment. This 
      finding was supported by the reversal of neurodegeneration in the cortex and in 
      the hippocampal regions of the brain. Furthermore, luteolin attenuated hepatic 
      steatosis and decreased the levels of serum aminotransferases and 
      hypertriglyceridemia. As an anti-inflammatory agent, luteolin cotreatment 
      similarly decreased the levels of hepatic inflammatory markers and increased the 
      levels of hepatic beta-catenin in TAM-induced fatty liver. CONCLUSIONS: Luteolin 
      improved the TAM-induced cognitive impairment and hepatic steatosis in rats by 
      alleviating inflammation and modulating hepatic beta-catenin levels.
CI  - Copyright (c) 2021 Elsevier B.V. All rights reserved.
FAU - El-Asfar, Rana K
AU  - El-Asfar RK
AD  - Department of Biochemistry, Faculty of Pharmacy, Ain Shams University, Cairo, 
      Egypt.
FAU - El-Derany, Marwa O
AU  - El-Derany MO
AD  - Department of Biochemistry, Faculty of Pharmacy, Ain Shams University, Cairo, 
      Egypt.
FAU - Sallam, Al-Aliaa M
AU  - Sallam AM
AD  - Department of Biochemistry, Faculty of Pharmacy, Ain Shams University, Cairo, 
      Egypt; Department of Biochemistry, School of Pharmacy and Pharmaceutical 
      Industries, Badr University in Cairo (BUC), Entertainment Area, Badr City, Cairo, 
      11829, Egypt.
FAU - Wahdan, Sara A
AU  - Wahdan SA
AD  - Department of Pharmacology and Toxicology, Faculty of Pharmacy, Ain Shams 
      University, Cairo, Egypt.
FAU - El-Demerdash, Ebtehal
AU  - El-Demerdash E
AD  - Department of Pharmacology and Toxicology, Faculty of Pharmacy, Ain Shams 
      University, Cairo, Egypt.
FAU - Sayed, Sayed A
AU  - Sayed SA
AD  - Department of Pathology, Al-Azhar Faculty of Medicine, Cairo, Egypt.
FAU - El-Mesallamy, Hala O
AU  - El-Mesallamy HO
AD  - Department of Biochemistry, Faculty of Pharmacy, Ain Shams University, Cairo, 
      Egypt; Department of Biochemistry, School of Pharmacy, Sinai University, Sinai, 
      Egypt. Electronic address: hala_elmosalamy@hotmail.com.
LA  - eng
PT  - Journal Article
DEP - 20210712
PL  - Netherlands
TA  - Eur J Pharmacol
JT  - European journal of pharmacology
JID - 1254354
RN  - 0 (Antineoplastic Agents, Hormonal)
RN  - 0 (beta Catenin)
RN  - 094ZI81Y45 (Tamoxifen)
RN  - KUX1ZNC9J2 (Luteolin)
SB  - IM
MH  - Antineoplastic Agents, Hormonal
MH  - Fatty Liver
MH  - Humans
MH  - Liver
MH  - *Luteolin
MH  - *Tamoxifen
MH  - beta Catenin
OTO - NOTNLM
OT  - Cognitive impairment
OT  - Fatty liver
OT  - Inflammation
OT  - Luteolin
OT  - Tamoxifen
OT  - beta-catenin
EDAT- 2021/07/16 06:00
MHDA- 2022/01/07 06:00
CRDT- 2021/07/15 20:13
PHST- 2021/02/28 00:00 [received]
PHST- 2021/06/12 00:00 [revised]
PHST- 2021/07/11 00:00 [accepted]
PHST- 2021/07/16 06:00 [pubmed]
PHST- 2022/01/07 06:00 [medline]
PHST- 2021/07/15 20:13 [entrez]
AID - S0014-2999(21)00490-8 [pii]
AID - 10.1016/j.ejphar.2021.174337 [doi]
PST - ppublish
SO  - Eur J Pharmacol. 2021 Oct 5;908:174337. doi: 10.1016/j.ejphar.2021.174337. Epub 
      2021 Jul 12.